This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 244.12% and 28.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Aytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Aytu BioPharma Inc. (AYTU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aytu BioPharma Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
5 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Play Stocks With Rising P/E to Realize Solid Gains
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Aytu Bioscience, Inc. (AYTU) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) closed at $1.39 in the latest trading session, marking a +1.46% move from the prior day.
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ASLAN Pharmaceuticals (ASLN) Looks Good: Stock Adds 8.7% in Session
by Zacks Equity Research
ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
by Zacks Equity Research
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Alnylam???s Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
by Zacks Equity Research
bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
Why Aytu BioScience (AYTU) Stock Might be a Great Pick
by Zacks Equity Research
Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
by Zacks Equity Research
Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.
Milestone Pharmaceuticals (MIST) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%
by Zacks Equity Research
Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
IDEAYA (IDYA) Looks Good: Stock Adds 10.2% in Session
by Zacks Equity Research
IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.